Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial
- PMID: 22537421
- PMCID: PMC3408568
- DOI: 10.1053/j.ajkd.2012.03.009
Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial
Abstract
Background: Conflicting relationships have been described between anemia correction using erythropoiesis-stimulating agents and progression of chronic kidney disease (CKD). This study was undertaken to examine the impact of target hemoglobin level on progression of kidney disease in the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.
Study design: Secondary analysis of a randomized controlled trial.
Setting & participants: 1,432 participants with CKD and anemia.
Intervention: Participants were randomly assigned to target hemoglobin levels of 13.5 versus 11.3 g/dL with the use of epoetin alfa.
Outcomes & measurements: Cox regression was used to estimate HRs for progression of CKD (a composite of doubling of creatinine level, initiation of renal replacement therapy, or death). Interactions between hemoglobin target and select baseline variables (estimated glomerular filtration rate, proteinuria, diabetes, heart failure, and smoking history) also were examined.
Results: Participants randomly assigned to higher hemoglobin targets experienced shorter time to progression of kidney disease in both univariate (HR, 1.25; 95% CI, 1.03-1.52; P = 0.02) and multivariable models (HR, 1.22; 95% CI, 1.00-1.48; P = 0.05). These differences were attributable to higher rates of renal replacement therapy and death for participants in the high hemoglobin arm. Hemoglobin target did not interact with estimated glomerular filtration rate, proteinuria, diabetes, or heart failure (P > 0.05 for all). In the multivariable model, hemoglobin target interacted with tobacco use (P = 0.04) such that the higher target had a greater risk of CKD progression for participants who currently smoked (HR, 2.50; 95% CI, 1.23-5.09; P = 0.01), which was not present for those who did not currently smoke (HR, 1.15; 95% CI, 0.93-1.41; P = 0.2).
Limitations: A post hoc analysis; thus, cause and effect cannot be determined.
Conclusions: These results suggest that a high hemoglobin target is associated with a greater risk of progression of CKD. This risk may be augmented by concurrent smoking. Further defining the mechanism of injury may provide insight into methods to optimize outcomes in anemia management.
Copyright © 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial.Clin J Am Soc Nephrol. 2020 May 7;15(5):608-615. doi: 10.2215/CJN.08900719. Epub 2020 Apr 3. Clin J Am Soc Nephrol. 2020. PMID: 32245781 Free PMC article. Clinical Trial.
-
Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.Am J Nephrol. 2013;37(6):549-58. doi: 10.1159/000351175. Epub 2013 May 25. Am J Nephrol. 2013. PMID: 23735819 Clinical Trial.
-
Correction of anemia with epoetin alfa in chronic kidney disease.N Engl J Med. 2006 Nov 16;355(20):2085-98. doi: 10.1056/NEJMoa065485. N Engl J Med. 2006. PMID: 17108343 Clinical Trial.
-
Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.Am J Kidney Dis. 2015 Jul;66(1):69-74. doi: 10.1053/j.ajkd.2014.12.012. Epub 2015 Jan 28. Am J Kidney Dis. 2015. PMID: 25636816 Free PMC article. Review.
-
Darbepoetin for the anaemia of chronic kidney disease.Cochrane Database Syst Rev. 2014 Mar 31;2014(3):CD009297. doi: 10.1002/14651858.CD009297.pub2. Cochrane Database Syst Rev. 2014. PMID: 24683046 Free PMC article. Review.
Cited by
-
Anemia and Hypoxia Impact on Chronic Kidney Disease Onset and Progression: Review and Updates.Cureus. 2023 Oct 9;15(10):e46737. doi: 10.7759/cureus.46737. eCollection 2023 Oct. Cureus. 2023. PMID: 38022248 Free PMC article. Review.
-
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.Cochrane Database Syst Rev. 2023 Feb 13;2(2):CD010590. doi: 10.1002/14651858.CD010590.pub3. Cochrane Database Syst Rev. 2023. PMID: 36791280 Free PMC article. Review.
-
Risk improvement and adverse kidney outcomes in patients with chronic kidney disease: findings from KNOW-CKD.J Nephrol. 2023 Apr;36(3):767-776. doi: 10.1007/s40620-022-01502-x. Epub 2022 Nov 24. J Nephrol. 2023. PMID: 36434262
-
Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors.Drugs. 2022 Nov;82(16):1565-1589. doi: 10.1007/s40265-022-01783-3. Epub 2022 Nov 9. Drugs. 2022. PMID: 36350500 Free PMC article. Review.
-
Association between hemoglobin and chronic kidney disease progression: a secondary analysis of a prospective cohort study in Japanese patients.BMC Nephrol. 2022 Aug 23;23(1):295. doi: 10.1186/s12882-022-02920-6. BMC Nephrol. 2022. PMID: 35999502 Free PMC article.
References
-
- Sharples EJ, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol. 2004 Aug;15(8):2115–2124. - PubMed
-
- Keane WF, Zhang Z, Lyle PA, et al. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol. 2006 Jul;1(4):761–767. - PubMed
-
- Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004 Aug;66(2):753–760. - PubMed
-
- Rossert J, Levin A, Roger SD, et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis. 2006 May;47(5):738–750. - PubMed
-
- Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16;355(20):2085–2098. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
